Provided by:
Penn Medicine
Continuing Medical and Interprofessional Education

Melanoma and Cutaneous Malignancy Tumor Board 2025-2026

Melanoma and Cutaneous Malignancy Tumor Board 2025-2026 - 11/11/2026
November 11, 2026
12:00 PM - 1:00 PM
PCAM South Tower Room 10-124

Target Audience
This program has been designed for DERMATOLOGY, DIAGNOSTIC RADIOLOGY, INTERNAL MEDICINE - Medical Oncology, PLASTIC SURGERY, RADIATION ONCOLOGY, OTOLARYNGOLOGY, DERMATOLOGY - Dermatopathology, MEDICAL GENETICS AND GENOMICS - Molecular Genetic Pathology, OBSTETRICS AND GYNECOLOGY - Gynecologic Oncology, PATHOLOGY - Dermatopathology, SURGERY - Complex General Surgical Oncology

Series Educational Objectives
After participating in this regularly scheduled series, participants should be able to:
1 Discuss a multidisciplinary approach to care for patients with melanoma and other cutaneous malignancies.
2 Describe how to accurately diagnose, stage, and develop appropriate treatment plans for patients with melanoma and other cutaneous malignancies.
3 Discuss treatment plans for patients with melanoma and other cutaneous malignancies using proven standardized methods and consider open investigative clinical trials.
4 Describe how to treat patients in a holistic view considering social, psychological, spiritual, and financial barriers.

Accreditation
In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For more information, please contact
Ahron Flowers, Samia White
(215) 360-0911, (215) 662-3002
aflow@pennmedicine.upenn.edu, Samia.White@Pennmedicine.upenn.edu

Check your transcript online at https://upenn.cloud-cme.com

Designation of Credit:

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC: up to **1** MOC points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **1** MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABS CC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to the ACCME for the purpose of granting ABS credit.
ABPath MOC: up to **1** MOC points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to the ACCME for the purpose of granting ABS credit.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours.

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*: None

Penn Medicine
Continuing Medical and Interprofessional Education

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Ravi Amaravadi, MD	Other Planning Committee Member	Ownership-Pinpoint Thrapeutics (Relationship has ended)|Advisor-Tasca |Grant or research support-Deciphera (Relationship has ended)|Grant or research support-Springworks (Relationship has ended)|Grant or research support-Merck & Co|Grant or research support-Bristol-Myers Squibb|Grant or research support-Pinpoint Therapeutics (Relationship has ended)|Advisor-Immunaccell (Relationship has ended) - 06/28/2026
Emily Chu, MD	Other Planning Committee Member	Nothing to disclose - 03/10/2026
David E Elder, MBBS	Other Planning Committee Member	Nothing to disclose - 06/24/2026
Rosalie Elenitsas, MD	Other Planning Committee Member	Nothing to disclose - 06/30/2026
Michael Farwell, MD	Other Planning Committee Member	Grant or research support-ImaginAb|Consulting Fee-Abcuro - 07/01/2026
Giorgos Karakousis, MD	Other Planning Committee Member	Grant or research support-Merck & Co - 06/25/2026
Kristin Kreider, PA-C	Physician Assistant Planner	Nothing to disclose - 10/08/2026
John N Lukens, MD	Other Planning Committee Member	Nothing to disclose - 07/10/2026
Suzanne McGettigan, CRNP RN	Nurse Planner	Speakers Bureau-Bristol-Myers Squibb|Consulting Fee-Merck & Co|Speakers

		Bureau-Regeneron Pharmaceuticals, Inc. - 08/25/2026
Tara C mitchell, MD	Co-Director	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck & Co|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Tempus|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb - 07/28/2026
John Miura, MD	Other Planning Committee Member	Grant or research support-Merck & Co - 06/26/2026
Meghan Mulligan, CRNP RN	Nurse Planner	Nothing to disclose - 06/29/2026
Lynn M Schuchter, MD	Course Director, Faculty	Nothing to disclose - 07/02/2026
Joanna L Walker, MD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.-SunPharma - 06/04/2026
Xiaowei Xu, MD	Other Planning Committee Member	Grant or research support-Incyte Corporation (Relationship has ended)|Advisor-Society for Immunotherapy of Cancer (Relationship has ended) - 04/21/2026

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected